Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Prothena and Management's Reporting
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(625)
•••
Comment by KayakerBCon Oct 01, 2022 10:34am
143 Views
Post# 34999270

RE:RE:RE:RE:RE:Prothena and Management's Reporting

RE:RE:RE:RE:RE:Prothena and Management's ReportingMeanwhile, if Bioasis is not fully reporting material events, circumstances and technology limitations, and is using language that purposefully obscures the status of Bioasis and xB3, would regulators be interested in that? Does the Prothena situation suggest deeper problems?

Would more transparency be nice?  Sure.  But this is not uncommon with small biotechs.  They are more opaque when possible suitors are kicking the tires, until there is solid news to report.  This never bothered you before.  At least not nearly to this extent. 

Purposely obsure? Deeper problems? Regulators?  I had to scroll up to double check who I'm responding to.  You're sounding like POOF with his FUD questions.  It makes one wonder if your soured relationship with Bioasis has affected your objectivity.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities